Navigation Links
Oncolytics Biotech(R) Inc. Announces Second Quarter 2010 Results
Date:7/29/2010

---- 25,662,961 34,701,071 ------------------------------------------------------------------------- Property and equipment 222,312 208,320 Long term investment 684,000 684,000 ------------------------------------------------------------------------- 26,569,273 35,593,391 ------------------------------------------------------------------------- ------------------------------------------------------------------------- LIABILITIES AND SHAREHOLDERS' EQUITY Current Accounts payable and accrued liabilities 3,639,572 4,226,933 ------------------------------------------------------------------------- Shareholders' equity Share capital Authorized: unlimited number of common shares Issued: 61,569,969 (December 31, 2009 - 61,549,969) 131,980,274 131,908,274 Warrants 2,073,441 4,511,441 Contributed surplus 16,157,171 13,734,743 Deficit (127,281,185) (118,788,000) ------------------------------------------------------------------------- 22,929,701 31,366,458 ------------------------------------------------------------------------- 26,569,273 35,593,391 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Oncolytics Biotech Inc. CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS (unaudited) Three Month Three Month Six Month
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent
2. Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
4. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
5. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
6. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
7. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
8. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
9. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
10. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
11. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... -- Imagine being able to probe and ... others. Being able to read faces and enjoy genuine ... anticipate their thoughts and actions like never before. Use ... create unique abstract paintings and video, or, play a ... first-person-shooter as it creates action, dialog, and outcomes based ...
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... May 21, 2015 /PRNewswire/ - RepliCel Life Sciences ... regenerative medicine company focused on the development of ... presentation at the International Society for Cellular Therapy ... Achilles tendinosis currently in a Phase 1/2 clinical ... th from 5:30 PM to 7:00 PM ...
(Date:5/20/2015)... May 20, 2015 Veracyte, Inc ... data demonstrating the ability of the company,s molecular ... from other interstitial lung diseases (ILDs) using samples ... potential to help thousands of patients avoid invasive, ... IPF diagnosis – a frequent challenge for physicians ...
Breaking Biology Technology:5 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5
... WI Governor Jim Doyle today announced his "Grow ... of the recommendations is to increase broadband and ... , ,Mike Tye, AT&T regional vice present of ... encouraged by the "Grow Wisconsin" initiative unveiled today ...
... gathered over 100 executives and leaders of Wisconsin's ... preview his new economic growth package. These leaders ... The Wisconsin Technology Council as well many biotechnology ... The message they heard from governor was his ...
... of Patients Compensation Fund could be illegal , ... expressed support yesterday for Gov. Jim Doyles Grow Wisconsin ... expressed support, but takes issue with the provisions for ... strongest criticism for Doyles proposed use of funds from ...
Cached Biology Technology:Governor Gathers Biotech Leaders at his Residence 2Republicans criticize Doyles growth package 2Republicans criticize Doyles growth package 3Republicans criticize Doyles growth package 4
(Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
(Date:5/10/2015)... Sweden , May 11, 2015 ... fingerprint sensors FPC1025 and FPC1155 from the distributor World Peace ... of FPC,s distributors in Asia . Deliveries ... sensors will be used by smartphone manufacturers in ... included in the communicated revenue guidance of + 1 000 MSEK ...
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... innovative system to specify in a simple, cost-effective and ... study of oxidative stress on sperm, a parameter rarely ... Jordi Benet and doctoral researcher Agust Garcia Peir from ... The CIMAB (Centre d,Infertilitat Masculina i Anlisis de Barcelona) ...
... reliable, and reversible. It would need to be long ... in BioMed Central,s open access journal Reproductive Biology ... to reduce sperm counts of male rats to levels ... potential as a male contraceptive was first reported nearly ...
... of human metabolism, researchers have identified thirty one regions ... circulating metabolites, i.e., small molecules that take part in ... studied metabolites are biomarkers for cardiovascular disease or related ... into the biological processes leading to common diseases. ...
Cached Biology News:Innovation in male infertility research 2Genetic regulation of metabolomic biomarkers - paths to cardiovascular diseases and type 2 diabetes 2
Alexa Fluor 647 anti-mouse Qa-2...
... Instrument System is ideal for developing ... Beadlyte reagents. The Luminex 100 Instrument ... software version 1.7, the XY platform ... offers $2000 in free Beadlyte products ...
EDG-6 Lysate Source: Cell Lysate Application: Western Blotting Control Form: IgG...
PC12 (rat phaeochromocytoma) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: